BRAF V600E-mutant mCRC

The first and only treatment approved specifically for patients with BRAF ^V600E-mutant mCRC, who have received prior systemic therapy^1,2

BRAF^V600E-mutant mCRC
is an area of high unmet need

Patients with BRAF^V600E-mutant mCRC have a poor prognosis^2,3

Overall survival is dramatically lower than for those with BRAF wild-type disease⁴
Patients with BRAF^V600E-mutant mCRC demonstrate a limited response to conventional chemotherapy-based regimens²

Mutations are common
in patients with mCRC^2,5

8-0%

of patients with mCRC have BRAF mutation^a

BRAF mutation is
a predictive marker

Overall survival is dramatically lower than for those with BRAF wild-type disease

^aThe V600E mutation accounts for approximately 95% of the activating mutations in BRAF in mCRC.⁶
ESMO, European Society for Medical Oncology.

HealthCare Professionals

This is an international website for BRAFTOVI dedicated to Healthcare professionals

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above.

Patients

This is an international website for BRAFTOVI dedicated to Healthcare professionals.

I am a patient outside the US

REFERENCES: 1. Braftovi Summary of Product Characteristics. Pierre Fabre Médicament, 2020. 2. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422. 3. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632-1643. 4. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054. doi: 10.1371/journal.pone.0047054. 5. Dienstmann R, Salazar R, Tabernero J. Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer. Am Soc Clin Oncol Educ Book. 2018;38:231-238.6. Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032-4038. 7. Erbitux Summary of Product Characteristics. Merck Europe B.V., 2020. 8. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer [protocol]. N Engl J Med. 2019;381(17):1632-1643. 9. Lai E, Pretta A, Impera V, et al. BRAF-mutant colorectal cancer, a different breed evolving. Expert Rev Mol Diagn. 2018;18(6):499-512. 10. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227-235. 11. ClinicalTrials.gov. Search results for phase 3 interventional trials of metastatic colorectal cancer with a BRAF mutation. Accessed March 27, 2020 https://clinicaltrials.gov/ct2/results?cond=Metastatic+Colorectal+Cancer&term=BRAF&cntry=&state =&city =&dist=&Search=Search&phas e=2. 12. European Medicines Agency Public Assessment Report (EPAR). Braftovi EMA/CHMP/175534/2020. 13.Tabernero J, Grothey A, Van Cutsem E et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021;39:273–284.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This is an international website for BRAFTOVI ®. IMPORTANT: the information on this website is based on the European Summary of Product Characteristics . Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country

BRAF V600E-mutant mCRC

BRAF^V600E-mutant mCRC
is an area of high unmet need

Patients with BRAF^V600E-mutant mCRC have a poor prognosis^2,3

Mutations are common
in patients with mCRC^2,5

Read more article

Mechanism of action

Study design

Overall Survival

HealthCare Professionals

Patients

BRAF V600E-mutant mCRC

BRAFV600E-mutant mCRC is an area of high unmet need

Patients with BRAFV600E-mutant mCRC have a poor prognosis2,3

Mutations are commonin patients with mCRC2,5

Read more article

Mechanism of action

Study design

Overall Survival

HealthCare Professionals​

Patients

BRAF^V600E-mutant mCRC
is an area of high unmet need

Patients with BRAF^V600E-mutant mCRC have a poor prognosis^2,3

Mutations are common
in patients with mCRC^2,5

HealthCare Professionals